Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') today announced that members of its executive team will present and host 1x1 meetings at the upcoming investor conferences, detailed below.
Jefferies Global Healthcare Conference
Dates: June 3 – 5 2025 | New York, USA
The executive team will participate in a fireside chat scheduled on Thursday, June 5, 2025, from 7:35 to 8:05 am EDT.
Goldman Sachs 46 th Annual Global Healthcare Conference
Dates: June 9 – 11 2025 | Miami, USA
The executive team will participate in a fireside chat scheduled on Tuesday, June 10, 2025, from 4:00 to 4:35 pm EDT.
In addition, members of the executive team will participate and represent the Company during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held from May 30 to June 3, 2025 in Chicago, Illinois.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Will Stripe SPAC or IPO in 2025?
Key Points Webull, Chime, and Circle Internet Group are some popular fintech companies that went public during the past year. In addition, SoFi Technologies and Robinhood Markets have emerged as leading fintech stocks over incumbents such as Block or PayPal. Although Stripe is a highly coveted private company, investors are curious if the company will become the next hot fintech IPO. 10 stocks we like better than SoFi Technologies › During the past several years, a number of technology-driven companies have burst onto the scene in search of disrupting the financial services industry. Amid a flurry of public offerings from the likes of Webull, Chime, Circle Internet Group, Robinhood Markets, and SoFi Technologies (NASDAQ: SOFI), financial services unicorn Stripe has remained a private company. But with a reported valuation of $91.5 billion, Stripe exceeds the market capitalizations of incumbent fintech businesses such as PayPal and Block by a considerable margin. Let's dig into the paths that competing fintech companies took to public exchanges in recent years. From there, I'll outline some factors that may weigh on Stripe's decision to pursue a public offering in the near future. How do companies go public? During a traditional initial public offering (IPO) process, a company will engage a number of investment banking firms such as Goldman Sachs, Morgan Stanley, or JPMorgan Chase to assist with the underwriting process. Banks put together detailed documentation covering the company's historical financial profile, key performance indicators (KPIs), and risk factors around the business. This information is packaged in a regulatory filing known as an S-1 made with the Securities and Exchange Commission (SEC). From there, banks and executives conduct a roadshow during which they market and pitch the IPO offering to institutional investors and wealth management firms. This process helps gauge investor interest and how the offering should be priced. Another way to list on the public exchanges is through a special purpose acquisition company (SPAC). SPACs are colloquially referred to as "blank check companies" on Wall Street. Essentially, a sponsor will take a shell company public to raise capital. From there, the goal is to use those funds to merge with a private company and take it public . SPACs can be attractive for businesses as they typically offer a faster route to going public compared to traditional underwriting protocols led by investment banks. For investors, SPAC mergers may be more accessible than traditional IPO companies -- where allocations are generally first reserved for institutional investors. How have fintech offerings fared in recent years? Although SPACs may sound appealing as they can provide investors with access to popular start-ups in hot industries more easily than a traditional IPO, there are some important points to consider about these companies. According to a SPAC study conducted at the University of Florida, one-year de-SPAC (the transition period after a merger announcement) returns averaged negative 46.3% between 2012 and 2022. The average three-year return was even worse, posting a return of negative 57.7%. When it comes to industry-specific metrics, the median de-SPAC returns between 2009 and 2025 for crypto companies was negative 66% while broader financial services companies returned negative 6%. No matter which way you cut it, SPACs in the fintech realm have been largely underwhelming. By contrast, since Robinhood went public back in 2021 using the traditional IPO process, the shares have surged by 192% -- handily topping the 48% return from the S&P 500. Both Circle and Chime completed IPOs about a month ago and have posted mixed returns so far. While Circle stock went to the moon initially, it has since pulled back considerably (yet still trades much higher than its IPO price). Chime's action has been relatively muted, likely due to investors realizing that competing neobank SoFi is much larger and more profitable -- calling into question Chime's growth prospects. Should Stripe go public in 2025? Overall, I think the results have largely been mixed for public offerings in the fintech sector in recent years. I think a big reason for this performance is that despite impressive growth and differentiated product offerings, questions remain over how neobanks and new brokerage platforms can really compete and disrupt industry incumbents. In addition, I think Stripe is likely weighing how macro factors such as potential changes to Federal Reserve monetary policy could affect its own business results, sentiment across the broader capital markets, valuations, and appetites for public offerings. Whether Stripe should go public really hinges on the company's needs and whether it makes sense from a strategic and operational perspective. Should you buy stock in SoFi Technologies right now? Before you buy stock in SoFi Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoFi Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Adam Spatacco has positions in SoFi Technologies. The Motley Fool has positions in and recommends Block, Goldman Sachs Group, JPMorgan Chase, and PayPal. The Motley Fool recommends the following options: long January 2027 $42.50 calls on PayPal and short September 2025 $77.50 calls on PayPal. The Motley Fool has a disclosure policy. Will Stripe SPAC or IPO in 2025? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Here are 3 ways to think about Nvidia stock
Fortunes have been made by many, thanks to investing in chip giant Nvidia (NASDAQ: NVDA). Nvidia stock has soared 1,576% over the past five years. It is now the most valuable listed company in the world. I continue to weigh my options when it comes to investing. I would be happy to own Nvidia stock in my portfolio — but I am not willing to pay the current price. In making my decisions, I have been trying to think about the share from different perspectives. Here are three of them. Like Amazon before the dotcom crash Artificial intelligence (AI) has some signs of being a stock market bubble. If that bubble bursts, for example because computing power progress means future chip demand is much less than expected, it would likely have a big impact on Nvidia. That helps explain why I am nervous about buying at the current Nvidia stock price. If it falls down I would then be nursing a paper loss, perhaps a sizeable one. Then again, Amazon fell 94% between the dotcom boom of November 1999 and September 2001. Still, since then it has gone up 76,600%. As a long-term investor, I do not mind sitting on a paper loss (even a sizeable one) if I continue to believe in the long-term investment case for a share. But while Amazon in 1999 could be an interesting comparison for Nvidia stock today, there is no guarantee latter would bounce back the way the former did. Amazon's market grew significantly. The market for AI chips may keep growing fast – but it could also be that after initial installations are complete, demand falls. A bubble waiting to burst? That leads me onto another potential way to view Nvidia stock: as a massive bubble waiting to burst. After all, the price-to-earnings (P/E) ratio is 56. That is higher than I would be willing to pay, though large tech stocks often do command high P/E ratios. But earnings have exploded at Nvidia in recent years. Last year's basic earnings per share of $2.97 were far more than double the prior year's $1.21 – and around 25 times higher than just five years previously. If the surging demand for AI chips turns out to be a blip rather than a long-term trend, Nvidia's eanings could come crashing back to earth. In such a scenario, even if Nvidia remained solidly profitable, its stock price may move far below where it currently stands. This is the risk that most puts me off investing at the current share price. Success story set to grow A third scenario could be that Nvidia might be like Microsoft or Apple at multiple points in their history – massively successful yet set to grow further, boosting an already costly-looking share price. Apple stock is up 131% in the past five years. But five years ago, Apple was already massively successful and one of the biggest companies on the market. Nvidia's proprietary technology, large customer base and proven business model have brought it a long way in a few years. Maybe it can do the same again over the next few years. The post Here are 3 ways to think about Nvidia stock appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool C Ruane has no position in any of the shares mentioned. The Motley Fool UK has recommended Amazon, Apple, Microsoft, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Yahoo
2 hours ago
- Yahoo
After Soaring Nearly 100% So Far This Year, Where Will Palantir Stock Be at the End of 2025?
Key Points Palantir has witnessed a meteoric rise in its share price thanks to the company's successful foray into the artificial intelligence (AI) arena. Several respected investors on Wall Street have been applying different approaches when it comes to investing in Palantir, making it hard to discern how "smart money" feels about the company. Palantir is trading for a historically high valuation, and broader buying and selling themes from institutional money managers could suggest a sell-off is on the horizon. 10 stocks we like better than Palantir Technologies › Outside of Nvidia, I'd argue that no other company has benefited from the tailwinds of the artificial intelligence (AI) revolution as much as data mining specialist Palantir Technologies (NASDAQ: PLTR). Over the last three years, shares of Palantir have gained more than 1,300%. Just this year alone, Palantir stock has rocketed by 97%. To put that into perspective, the S&P 500 and Nasdaq Composite indexes haven't even posted gains of 10% in 2025. While it can be tempting to follow the momentum in hopes of more outsize gains, smart investors understand that hope is not a real strategy. Let's explore the catalysts behind Palantir's generational run, and assess some recent trading activity to help discern whether Palantir stock could be headed even higher. The unprecedented rise in Palantir When AI first started to emerge as the next megatrend during late 2022 and early 2023, investors were consistently bombarded with news around big tech's splashy investments in the space. Microsoft plowed $10 billion into OpenAI, the maker of ChatGPT. Both Amazon and Alphabet invested hefty sums into a competing platform, called Anthropic. Tesla was touting its advancements in self-driving cars and humanoid robots. You get the drift -- the AI narrative largely hinged on the moves big tech was making. But in the background, Palantir was building. In April 2023, the company launched its fourth major software suite -- the Palantir Artificial Intelligence Platform (AIP). As the graph above illustrates, Palantir was a relatively slow-growth, cash-burning enterprise prior to the release of AIP. But since AIP's launch a little more than two years ago, Palantir's revenue has accelerated considerably. On top of that, the company has been able to command improving unit economics underscored by a sweeping transition to positive net income and generating billions in free cash flow. At the end of 2022, Palantir had 367 total customers. As of the end of the first quarter this year, Palantir boasted 769 total customers. Perhaps even more impressive is that the company's commercial customers (non-government) have risen by more than twofold over the last couple of years. To me, AIP is serving as a gateway for Palantir to expand its reach beyond federal contracts with the U.S. military, which is what Palantir is best known for. AIP represents a transformational shift as a defense contractor to a more ubiquitous software platform capable of penetrating the private sector, despite relentless competition from larger companies such as Salesforce or SAP. As a Palantir bull myself, I've been blown away by management's ability to outmaneuver big tech and deliver on lofty growth targets time and again. But as an investor, I can't help but wonder if the company's share price trajectory is sustainable. Is Wall Street trying to tell investors something? In addition to analyzing financial trends and operating metrics, investors can augment their due diligence process by listening to how Wall Street analysts talk about a company or even dig into the trading activity of notable investors. Thanks to a nifty tool called a form 13F, investors can access an itemized breakdown of all of the buys and sells from hedge funds during a given quarter. During the first quarter, famed billionaire investor Stanley Druckenmiller sold out of his fund's Palantir position. In addition, Cathie Wood has been trimming exposure to Palantir in Ark's portfolio as well. On the flip side, billionaire investors Ken Griffin and Israel Englander both added to their funds' respective Palantir positions during the first quarter. Given these dynamics, it might be hard to discern how Wall Street really feels about Palantir. I think there are some nuances to point out given the details above. First, both Druckenmiller and Wood have been in and out of Palantir stock in the past -- this is not the first time each investor reduced their exposure to the data analytics darling. On top of that, I think Griffin's and Englander's activity should be taken with a grain of salt. Both investors run highly sophisticated, multistrategy hedge funds. From time to time, some of this activity may include being a market maker. Although it may appear bullish that Palantir stock is held in Griffin's Citadel and Englander's Millennium Management portfolios, I wouldn't quite buy that narrative. Neither fund is necessarily known for holding positions for the long term. Moreover, as a multistrategy fund with a number of different teams and objectives, I think that it's highly likely that Citadel and Millennium have a layered and complex hedge strategy when it comes to owning a volatile growth stock such as Palantir. Where will Palantir stock be at the end of 2025? The chart below illustrates institutional buying and selling of Palantir stock over the last few years. Given that buying (the purple line) remains elevated over selling (the orange line), this could suggest that Palantir remains a favorite among institutional portfolios. However, as I expressed above, not all hedge funds and money managers have the same strategy. In other words, some of this elevated buying could be part of a broader, more complex trading strategy and less so an endorsement of long-term accumulation. Over the last few months, Palantir stock has become increasingly more expensive. In fact, the company is trading well beyond levels seen during peak days of the dot-com or COVID-19 bubbles. While it's impossible to know for certain where Palantir stock will be trading by the end of the year, smart investors know that nothing goes up in a straight line forever. A good indicator for how investors feel about Palantir's prospects should come after the company reports second-quarter earnings in a couple of weeks. As a reminder, shares fell off a cliff for a brief moment following the company's first-quarter blowout report. Expectations are rising with each passing report, and I would not be surprised to see Palantir stock sell off again -- even if its Q2 results are stellar. Given the convergence between institutional buying and selling, combined with Palantir's increasingly expensive valuation, I can't help but be cautious at this point. I do think a valuation correction could be in store sooner or later and would not be surprised if shares are trading for a considerably lower price by the end of the year. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Adam Spatacco has positions in Alphabet, Amazon, Microsoft, Nvidia, Palantir Technologies, and Tesla. The Motley Fool has positions in and recommends Alphabet, Amazon, Microsoft, Nvidia, Palantir Technologies, Salesforce, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. After Soaring Nearly 100% So Far This Year, Where Will Palantir Stock Be at the End of 2025? was originally published by The Motley Fool
